East Rutherford, NJ – March 29, 2019 – Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had been recognized across five categories in the annual CMO (Contract Manufacturing Organization) Leadership Awards, which were announced at a ceremony in New York, on March 20, 2019.
Cambrex has received CMO awards for five consecutive years, and this year, has been recognized in the following categories: compatibility, service, expertise, quality and reliability; and were noted for four individual attribute awards for accessible senior management, reputation, right first time, and strength of science.
“Cambrex is once again honored to be recognized as a leading supplier to the pharmaceutical industry,” commented Steven Klosk, President and Chief Executive Officer at Cambrex. He added, “With our recent acquisitions of Halo Pharma and Avista Pharma Solutions, we have created a leading, fully integrated small molecule CDMO across the entire drug life cycle offering more products and services to our customers. Being the recipient of a 2019 Leadership Award is a testament to the hard work of all our employees across the entire company.”
“The value and importance of the Life Science Leader CMO Awards grows each year. No industry awards are more meaningful than these recognizing the highest level of accomplishment as evaluated by actual customers. An award in any of the categories assessed, including capabilities, compatibility, expertise, quality, reliability and service, adds a clear acknowledgement of the leadership provided by the CMO recipient. Our congratulations to all of this year’s CMO Award winners — you keep the industry on the path to further success,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Life Science Leader magazine and Industry Standard Research.
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.
For more information, please visit www.cambrex.com
Director, Marketing and Communications
Tel: +44 7803 443 155